Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 17/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8543671 | 0.92 | MYB (1.00) | MYBMEN1LMNACYP1A2CYP3A4 | |
| SCHEMBL4335346 | 0.85 | MYB (1.00) | MYB | |
| SCHEMBL4327922 | 0.84 | MYB (0.83) | MYB | |
| SCHEMBL31237961 | 0.84 | MYB (0.80) | MYBMAPTRAB9A | |
| SCHEMBL8538963 | 0.84 | MYB (0.80) | MYBMAPTRAB9A | |
| SCHEMBL14478940 | 0.83 | MYB (0.73) | MYB | |
| SCHEMBL5044963 | 0.82 | MYB (0.89) | MYB | |
| SCHEMBL4331540 | 0.81 | MYB (0.87) | MYB | |
| SCHEMBL4325696 | 0.81 | MYB (0.78) | MYB | |
| SCHEMBL4327653 | 0.81 | MYB (0.75) | MYBMEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG (DE) | 2015-07-30 | — | — | US | disclosed |
| WO-2014041125-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | BADEN-WÜRTTEMBERG STIFTUNG GMBH (DE) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | CDKN1A, ING2, BCCIP | MYB 1211/4885MEN1 2917/4885LMNA 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.